market access

Mike Tremblay November 5, 2019

This is another article in my continuing commentary on market access and politics. The focus in this case is to look more closely at behaviours of people involved from government, industry and healthcare. Occupying these roles are people who bring their own psychological perspective to how they apply their knowledge and skills to their work. […]

Mike Tremblay October 8, 2019

This article is a continuation of my commentary on the politics of healthcare with particular focus on issues that likely interest those involved in market access and government relations. In this case, I’m commenting on government and market failure in healthcare. A future article will present what I call a ‘reform pathway’ laying out some […]

Mike Tremblay September 12, 2019

Market access is wrapped in the politics of health The attention politicians and stakeholders pay to healthcare and its challenges is a keen driver of the ease or difficulty companies experience with drug regulation and market access and has implications through the development process to discovery. How this manifests itself, in part depends on a […]

Mike Tremblay March 6, 2019

The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in multiple years of costed care so industry needs to assess how that can be understood […]

Mike Tremblay March 8, 2017

How can I be sure the medicine I take is genuine? Counterfeit medicines are a global problem, with trade in the billions of dollars. The World Health Organization estimates 8-10% of all drugs supplied globally are counterfeit. Counterfeits are a clear and present danger to human health. No country is immune from the risk. Fake […]

Mike Tremblay September 4, 2014

Sir Andrew Dillon, the erstwhile leader of NICE as said that it is irrational for the Cancer Drug Fund to pay for drugs that NICE has turned down. He’s right of course, it is irrational but is it wrong? The problem for Sir Andrew, and like-minded people, is that there is another logic that trumps […]